---
title: "Gossamer Bio jumps 10% in after-hours trading as Leerink upgrades to Outperform"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294117181.md"
description: "Gossamer Bio rose 10% after hours after Leerink upgraded the stock to Outperform."
datetime: "2026-07-28T21:32:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294117181.md)
  - [en](https://longbridge.com/en/news/294117181.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294117181.md)
---

# Gossamer Bio jumps 10% in after-hours trading as Leerink upgrades to Outperform

Gossamer Bio(GOSS.US) 盘后涨**10.14%**，现报**0.2259 美元**。消息面上，Leerink Partners 于 07/28/2026 将公司评级上调至 Outperform。此外，公司计划在 2026 年 9 月提交 seralutinib 治疗肺动脉高压的新药申请，并从 Chiesi 集团收回该药物的全球权利。公司还完成了债务重组，优化了资本结构。

### Related Stocks

- [GOSS.US](https://longbridge.com/en/quote/GOSS.US.md)

## Related News & Research

- [Gossamer Bio Restructures Debt, Secures Full Control of Lead Drug Candidate](https://longbridge.com/en/news/293964802.md)
- [Gossamer Bio shareholders approved convertible note exchange proposals at special meeting](https://longbridge.com/en/news/293920719.md)
- [Gossamer Bio Announces Final Convertible Notes Exchange Results](https://longbridge.com/en/news/290056187.md)
- [David E. Shaw Discloses Investment at Gossamer Bio with 9.5% Stake](https://longbridge.com/en/news/289530895.md)
- [Gossamer Bio says $18.95 million of 5% convertible notes due 2027 remain after exchange offer](https://longbridge.com/en/news/290049414.md)